Mobile Mpox Vaccination in New York City Provided Flexible Community-Responsive Vaccine Access During the 2022 Global Mpox Emergency - Summary - MDSpire
Advertisement
Mobile Mpox Vaccination in New York City Provided Flexible Community-Responsive Vaccine Access During the 2022 Global Mpox Emergency
To quantify and evaluate the mpox vaccination effort in NYC, emphasizing the effectiveness of community-responsive mobile vaccination strategies during the outbreak.
Key Findings:
3358 JYNNEOS doses administered at 363 events across 58 locations, demonstrating extensive outreach.
High uptake of the JYNNEOS vaccine at commercial sex venues, with up to 60% of attendees vaccinated at some events, indicating effective targeting.
Mobile vaccination demonstrated reduced racial and geographic disparities compared to non-mobile vaccinations, highlighting equity in health access.
No increase in mpox cases observed as commercial sex venues reopened with on-site vaccination, suggesting successful containment.
Interpretation:
The community-led vaccination strategy effectively addressed the mpox outbreak in NYC, particularly within LGBTQ+ networks, underscoring the critical role of tailored public health interventions in crisis situations.
Limitations:
Limited generalizability beyond NYC due to localized strategies, which may not apply to other regions.
Potential biases in self-reported data from event attendees, which could affect the accuracy of demographic assessments.
Conclusion:
The rapid, community-driven response to the mpox outbreak through mobile vaccination at key venues was successful in increasing vaccine uptake and preventing further spread, demonstrating the power of community involvement in public health initiatives.
Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.
